We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+1.01%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.07B
AUM Growth
+$158M
Cap. Flow
+$174M
Cap. Flow %
16.28%
Top 10 Hldgs %
64.66%
Holding
34
New
5
Increased
13
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$58.8M
2
NVTA
Invitae Corporation
NVTA
+$34.9M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$20.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.7M
5
QTTB icon
Q32 Bio
QTTB
+$8.62M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$9.24M
2
EVH icon
Evolent Health
EVH
+$6.92M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$5.96M
4
GILD icon
Gilead Sciences
GILD
+$5.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 81.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$90.6M 8.48%
884,800
-55,200
-6% -$5.96M
NVTA
2
DELISTED
Invitae Corporation
NVTA
$90.2M 8.44%
3,838,388
+1,638,388
+74% +$34.9M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$88.7M 8.3%
940,000
+91,352
+11% +$7.54M
CDXS icon
4
Codexis
CDXS
$158M
$86.5M 8.1%
5,073,780
+3,048,780
+151% +$58.8M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$73.2M 6.85%
400,000
– –
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$64.4M 6.03%
1,285,000
– –
FATE icon
7
Fate Therapeutics
FATE
$294M
$51.8M 4.85%
2,550,000
– –
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.63B
$50.9M 4.76%
335,000
+30,000
+10% +$3.65M
BLUE
9
DELISTED
bluebird bio
BLUE
$47.4M 4.43%
28,757
+1,158
+4% +$2M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.1B
$47.2M 4.41%
650,000
+205,000
+46% +$15.7M
DNTH icon
11
Dianthus Therapeutics
DNTH
$5.72B
$44.3M 4.15%
187,695
+22,488
+14% +$5.56M
BLFS icon
12
BioLife Solutions
BLFS
$1.56B
$39.4M 3.69%
2,428,571
– –
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
$36.5M 3.42%
965,000
-45,000
-4% -$1.73M
VYGR icon
14
Voyager Therapeutics
VYGR
$179M
$30.7M 2.87%
1,128,075
– –
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.84B
$24.7M 2.31%
495,000
+160,000
+48% +$8.55M
ILMN icon
16
Illumina
ILMN
$30.2B
$22.1M 2.07%
61,680
– –
GNMK
17
DELISTED
GenMark Diagnostics, Inc
GNMK
$21.8M 2.04%
3,365,000
– –
ADPT icon
18
Adaptive Biotechnologies
ADPT
$3.71B
$20.1M 1.88%
+463,125
New +$20.5M
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$19.7M 1.85%
1,770,000
+649,414
+58% +$7.43M
CNST
20
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$18.7M 1.75%
1,523,960
-33,039
-2% -$368K
SGMO
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$16.5M 1.54%
1,530,000
+450,000
+42% +$4.79M
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.8M 1.48%
300,000
– –
QTTB icon
23
Q32 Bio
QTTB
$460M
$14.6M 1.36%
41,389
+21,945
+113% +$8.62M
EDIT icon
24
Editas Medicine
EDIT
$399M
$11.9M 1.11%
480,000
– –
ALEC icon
25
Alector
ALEC
$168M
$10.2M 0.95%
551,039
+220,000
+66% +$4.47M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Casdin Capital held 34 positions worth $1.07B, up 17% from $910M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $174M of net new capital in Q2 2019, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Adaptive Biotechnologies: 463,125 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Spark Therapeutics, Inc. Common Stock, an estimated $5.96M trimmed.

  • Casdin Capital's largest Q2 2019 buy was Adaptive Biotechnologies: 463,125 shares worth $20.1M.
  • Casdin Capital added most to Codexis in Q2 2019, an estimated $58.8M increase.
  • Casdin Capital's biggest Q2 2019 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $5.96M.
  • Casdin Capital fully exited BeOne Medicines Ltd in Q2 2019, selling an estimated $9.24M.
  • Casdin Capital's ten largest holdings make up 65% of its $1.07B portfolio in Q2 2019.
  • Casdin Capital opened 5 new positions and closed 3 in Q2 2019.
  • Casdin Capital's portfolio value rose 17% quarter-over-quarter to $1.07B.

Based on Casdin Capital's 13F filing for Q2 2019, filed 13 Aug 2019.